Moss, 23 October 2025
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the third quarter of 2025.
Highlights include:
Sales of NOK 41.8 million in 3Q25, up 28% vs 3Q24 (31% organic growth). YTD 2025 sales of NOK 129.9 million up 19% (19% organic growth) versus the first nine months of 2024.
EBITDA of NOK 8.4 million in 3Q25 versus NOK 5.0 million in 3Q24. For the first nine months of 2025 the EBITDA is NOK 24.1 million versus 16.5 million for the same period last year.
Gross margin of 56% in 3Q25 versus 52% in 3Q24.
Sales of Cystatin C increased with 73% in 3Q25 compared to 3Q24 driven by strong performance in the US.
YTD sales to the US were NOK 21.7 million vs. NOK 8.1 million for the same period in 2024, partly due to a shift in warehouse for one of our largest customers. NOK 2.3 million or 10% of sales comes from new accounts acquired in 2025.
NT-proBNP advancements moving closer to final stages of verification. The timeline for full commercial launch is now estimated to take place during 4Q 2026.
The development project for a major IVD company entered successfully the next development phase (from proof-of-concept to optimization).
In 3Q several study sites have been activated and approximately 70 patients enrolled in the JIA COMPASS study that evaluates the diagnostic and prognostic use of GCAL in children with juvenile idiopathic arthritis (JIA).
Webcast
The company will present the results today at 09.00 am, followed by a Q&A session. The presentation will be held as a live webcast on the company's website:
https://www.gentian.com/investor-relation/presentations
The webcast will also be available on the company website after the presentation.
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Ole Sørlie, Business controller at Gentian Diagnostics ASA, on 23 October 2025 at 08:00 CEST.
About Gentian
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunoassays, specifically for infections, inflammation, kidney failure and congestive heart failure. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.